In postmenopausal women with osteoporosis or decreased BMD, longer treatment duration (1 to 5 years), increasing age, lower body weight, increasing time since menopause, lower baseline T score of lumbar spine, lower baseline serum levels of 25-OH vitamin D, and higher baseline serum levels of CTX and BSAP predicted better efficacy of ibandronate in improving BMD of the lumbar spine (Table 2). Here, PAX5 is linked to osteoporosis.